Cite
Abdel-Razeq H, Saadeh SS, Abu-Nasser M, et al. Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. Onco Targets Ther. 2018;11:2091-2096doi: 10.2147/OTT.S151821.
Abdel-Razeq, H., Saadeh, S. S., Abu-Nasser, M., Abdulelah, H., Marie, L., Salam, M., Ali, B. A., Ibrahim, M., & Rimawi, D. (2018). Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. OncoTargets and therapy, 112091-2096. https://doi.org/10.2147/OTT.S151821
Abdel-Razeq, Hikmat, et al. "Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients." OncoTargets and therapy vol. 11 (2018): 2091-2096. doi: https://doi.org/10.2147/OTT.S151821
Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Ali BA, Ibrahim M, Rimawi D. Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. Onco Targets Ther. 2018 Apr 11;11:2091-2096. doi: 10.2147/OTT.S151821. eCollection 2018. PMID: 29695917; PMCID: PMC5905529.
Copy
Download .nbib